Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

COPE – Coalition V, 2022
 
NCT04466540
RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
689/683 inconclusive
  • inconclusive 23 % decrease in hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
PATCH Cohort 1 (Amaravadi), 2021
 
NCT04329923
RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
15/13 inconclusive
    BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020
     
    NCT04304053
    RCThydroxychloroquinestandard of careCOVID 19 outpatientssome concern
    137/157 safety concern
    • statistically significant 25.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 177.2-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    COVID-PEP Severity (Skipper), 2020
     
    NCT04308668
    RCThydroxychloroquinecontrolCOVID 19 outpatientssome concern
    244/247 no results
      change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)
      COVID-PEP Severity (Skipper), 2020
       
      NCT04308668
      RCThydroxychloroquineplaceboCOVID 19 outpatientssome concern
      244/247 safety concern
      • statistically significant 1.8-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117)
      3 studies excluded by filtering options (2 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).